# Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy

> **NCT05918224** · PHASE2 · COMPLETED · sponsor: **West China Hospital** · enrollment: 160 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Streptococcus salivarius K12
- **DRUG:** Streptococcus salivarius K12 simulants

## Key facts

- **NCT ID:** NCT05918224
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918224, "Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT05918224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*